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1. Introduction
The HLA system includes a complex array of genes located on chromosome number 6 and
their molecular products that are involved in immune regulation and cellular differentiation.
Human leukocyte antigen (HLA) molecules are expressed on almost all nucleated cells, and
they are the major molecules that initiate graft rejection. There are three classical loci at HLA
class I: HLA-A, -B, and -Cw, and five loci at class II: HLA-DR, -DQ, -DP, -DM, and -DO. HLA
loci are the most genetically variable gene loci in human. Two hundred and twenty four loci
of HLA complex have been identified so far. Among these, 128 are functional loci that encode
proteins, and 39.8% of HLA genes are related to the immune system, particularly those belong
to class II loci. Almost all these genes display immune-related functions. Approximately 100
HLA genes loci have been cloned and named and at least 18 of them have alleles. Since these
loci have various amounts of alleles and each allele encodes a corresponding HLA antigen, the
HLA complex has the most abundant genetic polymorphism in the human immune system.
Systemic investigations of the alleles in HLA loci began in 1987. There were just over 10
identified alleles at that time. The allele numbers in HLA-I and HLA-II loci were increased to
100 and 50 respectively in 1989. The allele number of HLA-I and HLA-II reached 1028 in 2000.
As of July 2013, the total allele number of HLA loci has reached 9719. HLA-A, HLA-B and
HLA-C loci have 2365, 3015 and 1848 alleles respectively. DRA site has 7 and DRB site has 1456
alleles. DQA1 and DQB1 sites have 51 and 416 alleles respectively; DPB1 sites have 37 and 190
alleles, respectively (Fig 1). Theoretically, it is very difficult to find an unrelated donor with a
perfectly matched HLA genotype (at the allele level) in the general population.
The polymorphism of HLA makes it difficult to find a match between unrelated donor and
recipient in the allo-transplantation. Currently, the most commonly used HLA typing in organ
transplantations around the world is based on HLA-A, B, C and DR genes. There are up to
8600 alleles in these genes corresponding to more than 100 specific antigens. With the increas‐
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ing number of patients who need hematopoietic stem cell transplantation, the lack of appro‐
priate donors has become a significant challenge. Therefore, there is an urgent need to develop
novel scientific, practical, and feasible HLA typing methods in the field of organ and hema‐
topoietic stem cell transplantation.
Figure 1. Increasing number of HLA alleles from 1987 to July 2013
2. The influence of HLA compatibility on organ and hematopoietic stem
cell transplantation
The influence of HLA compatibility on organ transplant survival was analyzed in more than
150,000 recipients transplanted from 1987 to 1997 at transplant centers participating in the
Collaborative Transplant Study. A statistically highly significant effect of HLA matching on
graft and patient survival rates was found in the analysis of kidney transplants (P < 0.0001).
Ten years after transplantation, the graft survival rate of first cadaver kidney transplants with
a complete mismatch (6 HLA-A+B+DR mismatches) was 17% lower than that of grafts with no
mismatch. During the first post-transplant year, the class II HLA-DR locus had a stronger
impact than the class I HLA-A and HLA-B loci. During subsequent years, however, the
influence on graft survival of the three loci was found to be equivalent and additive. For
optimal graft outcome, compatibility at all three HLA loci is, therefore, desirable. The excellent
correlation of HLA matching observed in recipients of cadaver kidneys with very short
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ischemic preservation (0-6 hours) or recipients of kidneys from living unrelated donors
contradicts reports that short ischemia can eliminate the influence of matching.
Although HLA has a significant effect on graft outcome regardless of the state of presensiti‐
zation, the matching effect is potentiated in patients with highly reactive preformed lympho‐
cytotoxic antibodies. Among first cadaver transplant recipients with an antibody reactivity
against > 50% of the test panel, the difference in graft survival at 5 years between patients with
0 or 6 mismatches reached 30%. A collaborative project, in which molecular DNA typing
methods were employed, showed that the correction of serological HLA typing errors by more
accurate DNA typing results in a significantly improved HLA matching effect. Moreover,
matching for the class II locus HLA-DP, a locus that can be typed reliably only by DNA
methods, showed a significant effect in cadaver kidney retransplants, especially in the presence
of preformed lymphocytotoxic antibodies. The analysis of heart transplants showed a highly
significant impact of HLA compatibility on graft outcome (P < 0.0001). This result is of
particular interest because donor hearts are not allocated according to the HLA match. A
biasing influence of donor organ allocation (i.e. a preferential allocation of good matches to
good risk recipients) can, therefore, be excluded. In liver transplantation, neither matching for
HLA class I nor HLA class II could be shown to influence transplant outcome.
The first successful human bone marrow transplantation between identical twins in 1957 has
provided a new approach for the treatment of leukemia and other hematologic malignancies.
After the successful hematopoietic stem cell transplantation between unrelated donor and
recipient with matched HLA, a bone marrow donor registry was established in 1988 (National
Marrow Donor Program, NMDP) in the USA. Later on, a public cord blood bank was estab‐
lished. According to the World Marrow Donor Association (WMDA), as of July 2012, the
association has 68 bone marrow banks in 49 countries and regions. It also has 46 cord blood
banks in 30 countries and regions. The registered bone marrow and umbilical cord blood
donors have exceeded 20 million. Meanwhile, the technology of HLA typing has been
transformed from simple serotyping to more accurate genotyping. Although there are
hundreds of reports regarding the effect of HLA matching degree on the efficacy of hemato‐
poietic stem cell transplantation, these results are not consistent due to the differences in
sample size, disease type and stage, and HLA typing. In addition, the interpretation of HLA
genotyping results and their biological significance is becoming increasingly complicated. It
is challenging for the clinicians outside of the HLA field to select an unrelated donor with the
best-matched HLA. To meet this challenge, WMDA, NMDP of the USA and European
Federation of Immunogenetics (EFI) have provided guidelines for HLA typing.
3. The history of HLA typing strategy evolution
The technology for HLA typing has evolved from the serological level to the cellular level, to
the molecular level. Serotyping was the mainstream method for HLA type and has played a
critical role in organ transplantations before 1990s. However, most HLA antisera are polyclonal
and often have cross-reactions, making it difficult to distinguish antigens with subtle structural
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differences, and leading to misidentifications. Furthermore, many factors, such as a prolonged
transportation time of the blood sample and excessive amount of immature cells, may affect
the result of serotyping and cellular typing.
The development of polymerase chain reaction (PCR) and its application in biomedical
sciences has made the HLA typing at the DNA level possible. Therefore, using molecular
methods to type HLA at the DNA level has gradually replaced serotyping and cellular typing.
Commonly used DNA based HLA typing methods include PCR based sequence specific
primers (PCR-SSP), and PCR based restriction fragment length polymorphism (PCR-RFLP),
single-strand conformation polymorphism (PCR-SSCP), sequence-specific oligonucleotide
(PCR-SSO) and single nucleotide polymorphism (PCR-SNP).
In recent years, there have been emerged many advanced techniques applied into HLA typing,
such as microarray, reference strand mediated conformation (RSCA), PyrosequencingTM, flow
cytometry and DNA sequencing. In the early 1990s, new permissible mismatching strategies
based on HLA epitope and/or similarity between donor-recipient pairs were also established
and employed in clinical application.
4. Serological typing and cellular typing
4.1. Serological typing
4.1.1. Principle of microlymphocyto toxicity test technology
As early as 1956, Gorer et al. created a complement-dependent cytotoxicity assay for detecting
alloantibodies in mice. In 1964, at the University of California, Los Angeles (UCLA), the
Terasaki group introduced the microlymphocytotoxicity testing technique (microcytotoxicity
assay) to human leukocyte antigen (HLA) typing studies after making several improvements
and scaling down the procedures of HLA serological testing. Because the method was simple,
reliable, and precise, yielding reproducible results, it was widely adopted for serological study
of HLA and became an international standard technology recognized by the United States
National Institute of Health (NIH). HLA cytotoxic antibodies are IgG and IgM isotypes. In the
presence of complements, these antibodies are capable of binding with their corresponding
antigens on the surface of lymphocytes and inducing holes on the membrane. There is no such
effect if the lymphocytes do not carry the corresponding antigens. The principle for this
reaction is shown in Figure 2. Dead lymphocytes with damaged membrane can be observed
in a number of ways, the simplest of which staining with eosin or trypan blue. Dead cells are
stained and appear expanded due to incorporation of the dye; live cells are not stained.
Generally, the extent of the antigen-antibody reaction is determined on the basis of the
percentage of dead cells. NIH criteria are shown in Table 1.
Subsequently, an improved one-step method was developed in which antibodies, lympho‐
cytes, and complement are successively added and then stained and fixed. Results were
observed under a microscope. An operational diagram is shown in Figure 3.













  NIH method                  Positive reaction                Negative reaction 













Figure 2. Microlymphocytotoxicity test principle diagram
Score Mortality rate Definition
1 0-10 Negative
2 11-20 Negative
4 21-50 Weak positive
6 51-80 positive
8 81-100 Strong positive
0 Not determinable






Add 1 μl T or B cells  
One hour  
Room 
temperature 
Staining + fixation 
Result observation 
and report 
Figure 3. Schematic diagram of the one-step microlymphocytotoxicity test
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4.1.2. Technique for HLA monoclonal antibody typing
Microlymphocytotoxicity tests have significantly promoted HLA research in basic and clinical
applications since their introduction into serotyping. Some claim that serological typing
techniques are the basis of HLA research because they are such important tools. In modern
research, serological typing methods are still the main methods in HLA-I antigen typing.
However, as advancing HLA research has placed increasing demands on typing techniques,
shortcomings of serotyping methods have been identified, and these have been difficult to
overcome. (1) The standard antiserum in serological methods is mainly from human serum or
placenta. Because the rate of positive HLA antibody in sera is generally low, in particular, for
some rare antibodies, it can only be obtained through collection and screening of a large
number of serum samples. The technology for screening antisera is complex, difficult, and
resource and labor intensive. (2) There are significant numbers of strong cross-reactions that
can occur between serological tests; it is difficult to distinguish the sample antigen from the
subtype antigen. (3) A high variability between serum batches significantly affects the quality
of HLA typing reagents. (4) Serological match plates must be transported and preserved at
low temperatures (−80°C), constraints that are inconvenient for clinical applications.
In order to solve such problems in serological typing, Terasaki et al. in the late 1980s began to
develop HLA monoclonal antibodies to replace the standard antiserum. Formal production of
HLA monoclonal antibody matching reagents plates began in 1992, and its availability has
significantly improved the quality of HLA matching reagents. A comparison of the main
technical indicators of monoclonal antibody match plates with serological match plate is
shown in Table 2.
Main indexes Serum plate Monoclonal antibody plate
Identification of antigen determinants specific and non-specific specific
Specific univalent and polyvalent univalent
Titer low (<1:8) high (>20000)
Dosage limited almost unlimited
Anti-complement activity may exist non
Quality stable un-stable
Transportation Dry ice low temperature room temperature
Storage -80°C -20°C
Table 2. Comparison of key indicators of HLA monoclonal antibody typing plates with serological typing plates
4.2. Cellular typing
4.2.1. Homozygous typing cell
A homozygous typing cell (HTC) is homozygous for the A antigen, A/A. In the assay, HTCs
are used as stimulator cells. Cells to be examined contain an unknown antigen, X/X, and are
responding cells. In the reaction, a one way mixture lymphocyte culture (MLC) consists of
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HTC (A/A) stimulator cells and the responder cells (X/X) being examined. An MLC reaction
indicates that the responder cells could recognize the stimulator cells’s A antigens, and that
the responder cells being examined do not have A antigens. Absence of the MLC reaction
indicates that the cells being examined have A antigens. The examined cells could be either A
heterozygous (A/X) or A homozygous (A/A). In a repeated test, cells can be determined to
have the same antigen only when the cells are examined with a negative HTC cell reaction.
This procedure is also known as negative typing. This technique is rarely used because of the
difficulty in identifying HTC individuals by this method.
4.2.2. Primed lymphocyte typing technique
In 1975 SheChy and others established a primed lymphocyte typing method (PLT) based on
characteristics of a secondary response. It can specifically identify primed cells and it is also
known as positive typing. In the initial MLC of responding cells A and stimulation cells B, after
9–12 days of culture, responding cells A proliferated into lymphoblastoid cells, after which
they reverted to small lymphocytes. These inactive small lymphocytes were actually sensitized
memory cells, also known as primed lymphocytes (PLs). When PLs and former stimulator cells
were tested in a second MLC, there were very high responses within 20–24 hours. The
stimulator cells are called primed cells (priming) in this process. According to this principle,
experimental results of PLT depend on both priming and responding cells. Therefore, when
conducting PLT, PL grouped cells must be carefully selected. More than one type of PL should
be used in the identification of a PLT antigen. Preparation and sources of pretreatment cells
are complex and difficult, so this method is rarely used.
4.2.3. Mixed lymphocyte culture
In 1964, Bain and Bach et al. found that lymphocytes from two unrelated individuals could
stimulate each other in a mixed culture in a suitable in vitro environment. A lymphocyte could
be activated and converted into a mother cell, resulting in the proliferation. After further
research, other groups confirmed that mixed lymphocyte culture (MLC) is a good in vitro
model for studying the cellular immune response, especially transplantation immunity. MLC
technology was once widely used in organ transplantation and hematopoietic stem cell
transplant matching. Because the technology is complex, has long testing cycles, involves
radioactive elements, and has other drawbacks, it is gradually being replaced by the more
convenient and higher-resolution genotyping methods. I will not go into the details of that
method.
5. PCR based typing strategies
The technology for HLA typing has evolved from the serological level to the cellular level, to
the molecular level. Serotyping was the mainstream method for HLA type and has played a
critical role in organ transplantations before 1990s. However, most HLA antisera are polyclonal
and often have cross-reactions, making it difficult to distinguish antigens with subtle structural
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differences, and leading to misidentifications. Furthermore, many factors, such as a prolonged
transportation time of the blood sample and excessive amount of immature cells, may affect
the result of serotyping and cellular typing. These are the limitations of traditional HLA typing
methods. The development of polymerase chain reaction (PCR) and its application in bio‐
medical sciences have made the HLA typing the DNA level possible. Therefore, using
molecular methods to type HLA at the DNA level has been gradually replacing serotyping
and cellular typing. Commonly used DNA based HLA typing methods include PCR with
sequence specific primers (PCR-SSP), and PCR detection of restriction fragment length
polymorphism (PCR-RFLP), single-strand conformation polymorphism (PCR-SSCP), se‐
quence-specific oligonucleotide (PCR-SSO) and single nucleotide polymorphism (PCR-SNP).
5.1. PCR-SSP (PCR with sequence specific primers)
To identify point mutations in a DNA molecule, Newton invented the amplification refractory
mutation system (ARMS) for in vitro DNA amplification. The technique requires an allele
sequence specific 3’ primer for the PCR amplification. Otherwise the PCR reaction will not be
effective. This is because the Taq DNA polymerase used in the PCR reaction has 5’ to 3’
polymerase activity and 5’ to 3’ exonuclease activity but 3’ to 5’ exonuclease activity. Therefore,
the enzyme cannot repair the single mismatched nucleotide in the 3’ primer. In order to amplify
the allele with a specific sequence, the primer with the corresponding sequence is designed.
The conditions for PCR reaction are strictly controlled so that the amplification of the fragment
with its sequence perfectly matching to the primer is much more effective than the sequence
with one or more mismatched nucleotide. One mismatched nucleotide between the 3’ primer
and the template is sufficient to prevent the amplification. The PCR product is further analyzed
by electrophoresis to determine whether the amplicon corresponds to the anticipated primer-
specific product. Since the DNA sequence of HLA class I and class II genes are known, PCR
primers can be designed based on the specific sequence of each allele for PCR-SSP genotyping.
The encoding allele sequences of various HLA antigens can be amplified with sequence specific
primers. By controlling the conditions of PCR reaction, a specific primer can only amplify its
corresponding allele, not other alleles. Therefore, whether there is a PCR product can be used
to determine the presence or absence of a specific allele. The specificity of PCR product can be
further determined by agarose gel electrophoresis. Fig 4 shows the principle of PCR-SSP.
In the first step of PCR reaction, double-stranded DNA is denatured into single-stranded DNA.
In the second step, specific primers anneal to the template DNA. In the third step, double
stranded DNA is generated by TaqDNA polymerase by incorporating 4 types of dNTP into
the newly synthesized DNA strand. After 30 cycles of amplification, the target gene is increased
to 108 fold.
The main advantage of this method is that it is simple and fast, and the result is easy to interpret.
The heterozygosity can be easily detected as well. Therefore, PCR-SSP is the currently most
used method for HLA typing. There are several FDA approved high-resolution and low-
resolution detection kits available for HLA class I and class II typing. Many clinical laboratories
in China have been using this method for accurate pre-transplantation HLA typing. The
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procedure of PCR-SSP is shown in Fig 5. One disadvantage of this method is that it requires
multiple primers in order to amply all relevant alleles.
5.2. PCR-RFLP (restriction fragment length polymorphism)
Restriction endonucleases have unique recognition sites. Using computer software, restriction
endonucleases that can recognize HLA sequence polymorphism are chosen to digest the PCR
product. Because of sequence difference among the alleles, enzyme digestion will yield DNA
fragments with unique patterns of length, which can be distinguished by electrophoresis.
Compared to serotyping, PCR-RFLP method is specific, simple and rapid and does not require
probes. It can accurately detect single nucleotide difference and two linked polymorphic sites.
The disadvantage of this method is that if the enzyme cannot completely digest the PCR
product, the DNA fragments with similar lengths may be difficult to distinguish after electro‐
phoresis. In addition, alleles need to have endonuclease recognition sites. Furthermore, PCR-
RFLP cannot distinguish certain HLA heterozygosities. It requires multiple endonucleases for
Figure 4. The diagram of PCR reaction
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those alleles with high polymorphism such as HLA-DRB1, and may produce complicated
restriction maps. For these reasons, this method is rarely used for HLA typing nowadays.
5.3. PCR-SSCP (single-strand conformation polymorphism)
Orita et al in Japan have found that single-stranded DNA fragment has complex spatial
conformation. The three-dimensional structure is generated by the intramolecular interactions
among the base pairs. Changing of one nucleotide will affect the spatial conformation of the
 (a) (b) 
(c) (d) 
(e) (f) 
(a) DNA polymerase and DNA sample are added to the tube containing PCR reaction buffer and dNTP. (b) 10 μl of
mixture of DNA and D-mix is added to the SSP kit. The negative control does not have this mixture. (c) PCR amplifica‐
tion, (d) electrophoresis ( 2-4 min) (e) Automatic gel imaging system, (f) Analysis of the result by software
Figure 5. The process of PCR-SSP
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DNA strand, more or less. Single stranded DNA molecules have their unique size exclusion
characters in polyacrylamide gels due to their molecular weights and three-dimensional
structures. Therefore, they can be separated by non-denaturing polyacrylamide gel electro‐
phoresis (PAGE). This method is sensitive enough to distinguish molecules with subtle
structural differences, and is called single-stranded conformation polymorphism (SSCP). The
authors later applied SSCP in the detection of mutations in PCR products and developed PCR-
SSCP technique, which has further improved the sensitivity and simplicity for mutation
detection.
This method is simple, rapid, sensitive, requiring no special equipment and suitable for clinical
applications. However, this method can only detect mutations. The location and the type of
the mutation need to be determined by sequencing. In addition, the conditions of electropho‐
resis need to be tightly controlled. Furthermore, point mutations in certain locations may have
no effect or little effect on the DNA conformation. Therefore, different DNA molecules may
not be able to separate by PAGE due to these reasons and other factors. Nevertheless, this
method has a relatively high detection sensitivity compared with other methods. It can detect
mutations in unknown locations in the DNA molecule. Takao has demonstrated that SSCP can
detect 90% single nucleotide mutations in a DNA fragment smaller than 300bp. He believes
that most of known single nucleotide mutations can be detected by this method. Mutant DNA
molecules can be separated and purified by PAGE due to the different migration rates, and
the mutation can be eventually identified by DNA sequencing.
In SSCP analysis, the separation of single stranded DNA by non-denaturing PAGE is not just
based on their molecular weights and electric charges, but also on the retention force caused
by their spatial conformations. Therefore, the migration rate of a DNA fragment does not
reflect its molecular size. Since the wild type and mutant DNA molecules may migrate very
closely and be difficult to be distinguished, it is generally required for DNA molecules to
migrate for more than 16-18 cm in the gel. Mobility is calibrated using reference DNA as an
internal control. Because of these reasons, this method cannot clearly determine the HLA
genotype.
5.4. PCR-SSO (sequence specific oligonucleotide)
In PCR-SSO, specific probes are synthesized according to the sequence in the HLA polymor‐
phic region. The target DNA fragment is amplified in vitro first. Then a specific probe will be
hybridized to the PCR product under certain conditions based on base pair complementarity.
The hybridized product can be detected by radioactive or non-radioactive signals. There are
two types of SSO method, direct hybridization and reverse hybridization. In the direct
hybridization, the PCR product is fixed on the membrane while in the reverse hybridization,
the probe is fixed on membrane. Figure 6 is the diagram of PCR-SSO.
In 1986, Saiki et al were the first to report the analysis of DQA1 polymorphism using PCR and
4 ASO probes. Michelson has typed the DR loci by serotyping and PCR-SSO in 268 specimens.
The success rate of serotyping is 91.0% while the success rate of PCR-SSO is 97.0%. Overall,
PCR-SSO has a high success rate, a wide source of reagents, a high specificity and resolution.
It can detect the difference of one nucleotide. In addition, PCR-SSO can be used for a large
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number of samples with accurate and reliable results. However, this method is time consum‐
ing. It often takes a few days and needs a large amount of probes. In addition, it is difficult to
detect heterozygous alleles, particularly those of the complicated HLA-DRB1 genes.
Overall, PCR-SSO is an accurate HLA genotyping method, and can identify all known HLA
alleles for accurate analysis of HLA polymorphism. HLA is a super gene family and new alleles
are continuously been identified. SSO probes can only be designed based on the sequences of
known alleles. Although PCR-SSO may discover new HLA polymorphism through its
hybridization pattern, dot-hybridization often leads to false positives. In addition, when an
allele is identified in the sample, it is difficult to determine whether the allele is homozygous
or heterozygous. Therefore, the HLA allele frequency and haplotype frequency cannot be
precisely determined by this method.
5.5. PCR-SNP (single nucleotide polymorphism)
Single nucleotide polymorphism (SNP) is the inheritable and stable biallelic single nucleotide
difference. In the human genome, every 1000 base pairs have one to 10 SNPs. SNP may have
some regulatory functions in gene expression and protein activity. High SNP density has been
found in HLA class I genes with one SNP in every 400bp, setting the basis for high-throughput
MHC-SNP analysis. Compared with other methods, SNP is less time consuming and with a
low cost. Gou et al have developed a simple and effective oligonucleotide microarray to detect
SNPs in the coding sequence of HLA-B locus. Based on the known polymorphism in the exon
Figure 6. The diagram of PCR-SSO process
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2 and 3 of HLA-B genes, 137 specific probes were designed. In a double-blind experiment,
these probes were used in the PCR-SNP analysis of 100 specimens from unrelated individuals.
The result showed that this method could explicitly identify all SNPs in the HLA-B locus. Bu
Ying et al have established a rapid, efficient and cost effective SNP detection method using a
single tube.
In this method, 4 primers are used for the PCR amplification. Two primers are used to amplify
the DNA fragment containing the SNP region, and the other two primers are SNP specific. The
primer extension error is significantly reduced when 4 primers simultaneously carry out the
PCR reaction, thereby the accuracy of SNP analysis is greatly improved. With the development
of third-generation genetic markers, it is expected to find a series of single nucleotide poly‐
morphisms in the HLA complex, and generate high-density SNP maps. In order to develop
SNP technology into a simple and effective HLA typing method, production of high-density
SNP maps in the HLA regions and development of HLA-SNP genotyping kits have been
proposed in the 13th IHWC conference.
6. Reference-strand-mediated conformation analysis (RSCA)
Arguello et al invented the double-stranded conformation analysis (DSCA) technique in 1998
for the detection and analysis of gene mutations and complex polymorphic loci. Based on this
technique, reference strand mediated conformation analysis (RSCA) has been developed. This
is a major technical breakthrough in HLA typing. This technique combines sequencing and
conformational analysis to overcome the limitations of the methods that just employ DNA
sequencing or conformational analysis. The principle of RSCA is that fluorescent labeled
reference strand is hybridized with the amplified product of a specific gene to form stable
double stranded DNA with unique conformation. After non-denaturing polyacrylamide gel
electrophoresis or capillary electrophoresis, HLA alleles can be detected by laser scanning and
computer software based analysis. Figure 7 is the diagram of RSCA.
Compared with PCR-SSP, the most commonly used method of HLA genotyping, RSCA has
the following advantages: (1) high resolution and sensitivity. RSCA is based on the differential
migration rate of fluorescent-labeled double stranded DNA during the electrophoresis. Alleles
with different sequences will produce DNA duplexes with different spatial structures after
hybridization with their fluorescent labeled probes. Two alleles with one nucleotide difference
will cause a change in the spatial structure of hybridized duplex, resulting in an altered
migration rate in electrophoresis. Therefore, RSCA can distinguish the alleles with a single
nucleotide difference. For example, HLA*0207 and A*0209 alleles only differ one nucleotide
at the site 268 of exon 2 and 3. In this site, A*0207 has a G while A*0207 has an A. Likewise,
HLA-A*0224 and A*0226 only differ one nucleotide. These alleles all can be distinguished by
RSCA. (2) high reproducibility. In RSCA, each lane in the non-denature polyacrylamide gel
has markers and each gel has a DNA ladder. Therefore, the alteration caused by different gels
or lanes can be eliminated. (3) new allele or mutation identification. RSCA is based on the
electrophoretic mobility difference caused by different spatial structure of the duplexes after
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allele-FLR hybridization. New alleles or mutations will have electrophoretic mobility different
from that of known alleles. (4) RSCA can be applied at a large scale with a low cost.
Figure 7. The diagram of RSCA
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The disadvantages of RSCA are (1) time-consuming for a single sample; (2) requiring high
quality samples; PCR-SSP requires 10-100ng/ml of DNA, which can be obtained with a regular
DNA purification kit from patients even with a low amount of white blood cells. However,
RSCA requires 50-100ng/ml of DNA. It may require an increased amount of blood sample for
patients with low levels of white blood cell in order to obtain sufficient DNA; and (3) insuffi‐
cient database.
7. PyrosequencingTM — A high-resolution method for HLA typing
Pyrosequencing is a new HLA genotyping technology based on real time sequencing during
DNA amplification. The reaction system contains 4 enzymes (DNA polymerase, ATP sulfur‐
ylase, luciferase and apyrase), substrate (APS: adenosine 5’ phosphosulfate), fluorescein
(luciferin), primers and the single stranded DNA template. After one type of dNTP (dATP,
dTTP, dCTP and dGTP) is added to the reaction system, it will be incorporated into the newly
synthesized chain if it is complementary to the nucleotide on the template. Incorporation of
dNTP will generate the same molar amount of pyrophosphate (PPi). ATP sulfurylase converts
APS and PPi into ATP, which provides energy for luciferase to oxidate luciferin and emit light.
The amount of light signal is proportional to the amount of ATP. The optical signal is detected
by a CCD (charge couple device) camera and generates a peak in the pyrogram. The principle
of Pyrosequencing is shown in Fig 8.
The height of each signal’s peak is proportional to the number of incorporated nucleotide.
Unincorporated dNTPs and excessive ATP are converted to dNDPs, which are further
converted to dNMPs by apyrase. The optical signal is quenched and the system is regenerated
for the next reaction. The next dNTP can be added to the system to start the next reaction after
the unincorporated dNTPs and excessive ATP are removed. The reaction cycle continues until
the complementary DNA strand is synthesized. Under the room temperature, it takes 3-4
seconds from polymerization to light detection. In this system, 1 pmol of DNA will generate
6x1011 pmol of ATP, which in turn yields 6x109 pmol of photon with a wavelength of 560nm.
The signal can be easily detected by a CCD camera. For the analysis of DNA with unknown
sequence by Pyrosequencing, a cyclic nucleotide dispensation order (NDO) is used. dATP,
dGTP, dTTP and dCTP are sequentially added to the reaction. After one nucleotide is incor‐
porated, the other three will be degraded by the apyrase. For the DNA with known sequence,
non-cyclic NDO can be used and will yield a predicted pyrogram. The sequence of the
complementary DNA strand can be determined based on the NDO and peak value in the
pyrogram.
Since nucleotides are differentially incorporated, Pyrosequencing can produce high-resolution
results. Typing HLA-DRB1*04, 07 and DRB4* in the donor’s DRB genes by Pyrosequencing
not only yields the same result as using the SSOP typing kit, but also produces the result with
a higher resolution. Compared with SSP, SSOP, direct or reverse hybridization, Pyrosequenc‐
ing can be used to solve ambiguous allele combinations of HLA-DQ and HLA-A/B in a short
time. The types of HLA-DQB1 and HLA-DRB alleles have been accurately determined by
Pyrosequencing.
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An inherent problem with this technology is the de novo sequencing of polymorphic region
in heterozygous DNA, although polymorphism can be detected in most cases. When the
nucleotide in the polymorphic region is altered, synchronized extension can be achieved by
the addition of the substituted nucleotides. If there is a deletion or insertion in the polymorphic
region, and the deleted or inserted nucleotide is the same as the adjacent nucleotide on the
template, the sequence after the polymorphic region will be synchronized. However, if the
deleted or inserted nucleotide is different from the adjacent nucleotide on the template, the
sequence reaction can be out of phase, making the subsequent sequence analysis difficult.
Another issue with this technology is the difficulty in determining the number of incorporated
nucleotides at the homopolymeric region. The light signal will become nonlinear after the
incorporation of more than 5-6 identical nucleotides. Studies on the polymerization efficiency
of the homopolymeric region have shown that it is possible to incorporate less than 10 identical
nucleotides in the presence of apyrase. However, it needs specific software algorithm of signal
integration to determine the precise number of incorporated nucleotides. For re-sequencing,
the nucleotide is added twice to ensure complete polymerization in the homopolymeric region.
Another limitation of this technology is the length of the sequencing.
8. Application of flow cytometry in HLA typing
Flow cytometry has failed to become a main method for HLA typing since it was applied to
the field of immunology for the first time in 1977. This is mainly due to the large number of
specific probes required for HLA typing. The flow analyzer LABScan100 that combines the
Figure 8. The principle of Pyrosequencing
HLA and Associated Important Diseases126
flow cytometry and reverse SSO technology has a trend to replace three conventional methods,
SSO, SSP and SBT (sequence-based typing, direct sequencing), in HLA typing.
On a suspension platform, multiple types of color-coded beads conjugated with SSO probes
specifically bind to the single stranded DNA. Each type of bead has its unique spectral
characteristics due to the different amount of fluorescent dye conjugated to the beads. When
beads pass through a flow cytometer, the difference in the light scattering pattern from various
angles can distinguish HLA genotypes.
Currently, LabType TM SSO is a relatively more mature technique compared with others in
HLA typing. Its unique advantage is that thousands of molecules can be simultaneously
analyzed in a matter of seconds. Therefore, this technique can be used for a large-scale analysis.
Overall, this technique has following main advantages. (1) It has increased accuracy due to the
automated detection system. (2) The workload and reagent consumption are reduced. One
reaction tube can have 100 different SSO probes, thus greatly reducing the workload and
reagent consumption. (3) It produces rapid and objective results. The ambiguous results can
be avoided with Specialty Probe Technology TM (SP Technology). (4) Unlike regular flow
cytometry that requires fresh samples, this technique can examine the sample at any time upon
request or retrospectively. DNA samples can be analyzed right after extraction or stored at –
20oC for more than 1 year without affecting the results. (5) The technique can analyze multiple
HLA loci with low, medium and high resolutions. (6) It can be used in laboratories with large
or small sample size. More than 100 probes can be put in one test tube for one sample or in a
96-well plate for 96 samples. The analysis of 96 samples takes less than 90 min after amplifi‐
cation. (7) The pollution to the environment and potential harm to the staff are reduced because
electrophoresis is not required in this method.
9. Gene chip or DNA microarray
In gene chip or DNA microarray, large amount of probe molecules (usually 6x104 molecules/
cm2) are attached to a solid surface. Labeled DNA samples are hybridized to the probes. The
amount and sequence information of the target can be determined by the intensity of the
hybridization signal. Gene chip or DNA microarray technology was first developed by
Affymetrix in the USA, and has been improved significantly within a few years. The technol‐
ogy is based on the principle of reverse dot hybridization. Thousands of oligonucleotide probes
representing different genes are spotted on a solid surface by a robot. These probes will bind
to radioactive isotope or fluorescent dye labeled DNA or cDNA through complementary
sequences. After autoradiography or fluorescence detection, signals are processed and
analyzed by computer software. The intensity and distribution of hybridization signal reflect
the expression level of the gene in the sample. The operation process of microarray is shown
in Fig 9. Balazs et al spotted amplified DNA samples on silicon chips and compared the
microarray results with PCR-SSO results in 768 specimens. It has been found that microarray
has a high sensitivity and specificity. The consistent rate of genotyping results from microarray
and PCR-SSO is 99.9%.
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Figure 9. The procedure of gene chip/microarray analysis
Compared with existing genotyping methods, gene chip or microarray has the following
advantages. (1) high intensity; The dot intensity on a chip can be higher than 6x104/cm2.
Therefore, probes to thousands of HLA-A, B, C, DR, DQ and DP sequences can be spotted on
a tiny chip of several square centimeters to obtain the information of individual HLA genes
simultaneously. (2) high resolution; It can obtain information at the allele level. (3) simple
operation; The results are generated by fluorescence scanning instead of gel electrophoresis,
which greatly simplifies the procedure and shortens operation time. (4) high sensitivity;
Signals are amplified twice with first PCR amplification of the template DNA and second
amplification of fluorescence signal. Therefore, the sensitivity is greatly improved. (5) high
accuracy; The intensity of the fluorescent signal generated by the perfect pairing of the probe
and the sample is 5 to 35 times higher than the signal generated by the probe and the sample
with one or two mismatched nucleotide. Accurate detection of fluorescent signal intensity is
the basis of the detection specificity. Studies have shown that the consistency between
microarray and Sanger sequencing in the detection of mutations and polymorphism is 99.9%.
(6) high efficiency; The whole process is highly automatic, which saves manpower and time
for data analysis. Genotyping of genes such as HLA-A, B, DR and DQ in multiple samples can
be done with one PCR reaction and hybridization on one chip. (7) high level of standardization;
Using a variety of multi-point synchronized hybridization and automated analysis, the human
error is minimized to ensure the specificity and objectivity. (8) low cost. Since the chip
fabrication and signal detection are all automatic, only small amount of probes and samples
are required. One chip can be used for the analysis of samples from multiple individuals, which
further reduces the cost. The biggest drawback of microarray analysis is its expensive equip‐
ment, which prevents it from becoming widely used. Only institutions with a large program
can afford the equipment.
10. DNA sequencing technology
For the analysis of gene structure, sequencing is the most direct and accurate method. In this
case, the DNA fragment is amplified by PCR and followed by sequencing. The basic process
HLA and Associated Important Diseases128
of this method is shown in Figure 10. Since the entire nucleotide sequence of the amplified
fragment is obtained, this is the most reliable and through genotyping method. It can not only
identify the sequence and genotype, but also lead to the discovery of new genotypes. Currently,
the newly identified HLA alleles can only be verified by sequencing. It has been reported that
if the HLA type cannot be determined by serotyping or the results from PCR-SSP and PCR-
SSOP are inconsistent, sequence-based typing (SBT) often can yield accurate and reliable
results with a high resolution. Hurley et al have typed HLA alleles by PCR-STB in 1775 bone
marrow transplant patients and unrelated donors in NMDP, USA. The study has found that
the degree of HLA allele mismatching between the recipient and donor of bone marrow
transplantation is much higher than previously thought after examining the antigen matching
results of HLA-A, HLA-B and HLA-DR.
The advantage of SBT over PCR-SSP and PCR-SSOP is its ability to analyze the entire gene
sequence including the non-polymorphic region. SBT can be used not only for DNA sequenc‐
ing but also for cDNA sequencing to determine gene expression. With increasing popularity
of DNA sequencing technology, the PCR-SBT method has gained much attention for geno‐
typing. PCR-SBT has advantages over other typing methods in terms of accuracy, efficiency
and the degree of automation. Specialized software and solid phase sequencing kits with
automatic loading are available for HLA typing. In addition, the cost of DNA sequencing has
been greatly reduced. Therefore, PCR-SBT is an ideal method for HLA typing in researches.
With the further decrease in the cost of automatic sequencing, this genotyping method will be
widely used.
Currently, PCR-SBT is the gold standard of HLA typing. This method has several advantages.
(1) It can accurately determine gene type in the exon 8 by a high-resolution sequencing,
sufficient to meet the need in researches and clinics. (2) It can analyze more than 15,000 samples
every month with high throughput detection. (3) Automated SOP and advanced data man‐
agement system can reduce human error. (4) It has high quality assurance. Ten percent blind
samples are used repeatedly as internal quality control and 100% accuracy is achieved for 10
consecutive times using UCLA external quality assurance samples. The results are confirmed
by SSP. (5). It may lead to the discovery of new alleles. (6) HLA genotype can be updated by
re-analyzing the sequence after the HLA database is updated.
11. HLA matchmaker
In organ transplantation, the degree of matching is generally determined by counting the
number of mismatched HLA-A, B, DR antigens of the donor. It is well known that the zero-
antigen mismatches have the highest success rates but why do so many mismatched trans‐
plants do so well? The answer to this question may be related to the fact that antibodies
produced against HLA mismatches are significant risk factors for transplant failure. An
important consideration is that HLA antigens have multiple epitopes that can be recognized
by specific antibodies. The original description of the epitope repertoire was based on
serological cross-reactivity between HLA antigens and antibody specificities against so-called
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private and public determinants. Elucidation of three-dimensional molecular structures and
amino acid sequence differences between HLA antigens has made it possible to define the
structural basis of HLA epitopes. The general concept is that HLA epitopes are determined by
polymorphic amino acid residues on the molecular surface. Three-dimensional modeling of
HLA antigens has revealed many clusters of polymorphic residues. In spite of this highly
complex polymorphism it has become possible to determine HLA compatibility at the
structural level.
HLA MATCHMAKER is a computer algorithm that assesses human leukocyte antigen (HLA)
compatibility at a structural level by intralocus and interlocus comparisons of polymorphic
amino acid sequences of HLA molecules. In its first version, each HLA antigen was seen as a
chain of short, lineal sequences of polymorphic amino acids in an antibody-binding position
(triplets); these triplets are considered the key elements of epitopes able to induce specific
antibody production. The most recent version—Eplets HLA Matchmaker—introduces the
concept of sequences of polymorphic amino acids in discontinuous positions that create on the
surface of the HLA molecule conformational epitopes. The eplet version provides a broader
repertoire of structural defined HLA epitopes and may provide a more accurate evaluation of
the HLA compatibility.
HLA Matchmaker is based on the following principles. First, each HLA antigen is represented
by different chains of epitopes structurally defined as potential immunogenic particles capable
of inducing specific antibody production. Second, patients cannot produce antibodies against









Figure 10. The diagram of DNA sequencing
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epitopes present on their own HLA molecules. Initially, the program was developed to increase
the chances of finding acceptable donors for hypersensitized patients. Subsequently, Duques‐
noy et al demonstrated that it might also be useful in predicting the risk of graft loss according
to the number of HLA-I mismatch triplets. This was proved in sensitized and nonsensitized
patients. Haririan et al also showed that this triplet compatibility could give information about
renal graft outcome in African-American patients. Nevertheless, Laux et al based on their own
studies questioned the predictive role of triplet compatibility in graft survival. Other authors
have also questioned the consistency of the epitopes in which this algorithm is based, pointing
out that they might not be the unique epitopes inducing antibody formation. HLA Matchmaker
has also been evaluated for clinical use in the selection of donors in pediatric renal desensitized
receptors and HLA allosensitized thrombocytopenic patients. It has also been applied in
unrelated bone marrow transplantation, lacking definitive proof of its benefit in patient
survival.
12. HistoCheck
When there is no genotypically identical sibling and there are several alternative potential
donors that all have a mismatch at an HLA class I or II locus, the allogenicity of mismatches
may be estimated using the Sequence Similarity Matching concept described by our working
group. In this concept the amino acid differences between HLA alleles are evaluated and rated
with regard to position within the molecule (peptide binding, contact with the T-cell receptor)
and with regard to functional similarity of amino acids within proteins. This procedure led to
a dissimilarity score (allogenicity index) whereby high values represent high dissimilarity.
When there are several mismatched donors, dissimilarity scores may be calculated for any of
them, and the donor with the least may be preferred.
The importance of HLA-DPB1 matching for the outcome of allogeneic hematologic stem cell
(HSC) transplantation is controversial. Previous findings identified HLA-DPB1 alleles as
targets of cytoxic T cells mediating in vivo rejection of an HSC allograft. These HLA-DPB1
alleles encode T-Cell epitopes shared by a subset of HLA-DPB1 alleles that determine non-
permissive mismatches for HSC transplantation. Retrospective evaluation of transplantations
showed that the presence of non-permissive HLA-DPB1 mismatches was correlated with
significantly increased hazards of acute grade II to IV graft-versus-host disease and trans‐
plantation-related mortality but not relapse as compared with the permissive group. Based on
these findings, an algorithm for prediction of non-permissive HLA-DPB1 mismatches was
developed (details in http://www.mh-hannover.de/institute/transfusion/histocheck/).
13. Conclusion
Currently, PCR-SSP genotyping is a commonly used method for HLA typing in clinical
laboratories worldwide. Like SSP method, PCR-SSP method depends on specific primers for
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genotyping. Although the process is simple and rapid, high-resolution genotyping requires a
large number of sequence specific primers, which leads to a high cost and prolonged operation
time. Similarly, SSO technique is based on the sequence-specific oligonucleotide probes. High-
resolution genotyping by SSO significantly increases the cost and complexity. Therefore, it is
rarely used for HLA typing today. PCR-SNP is a simple and fast method with a high resolution.
PCR-SNP is expected to become more popular in HLA typing as the technology continues to
improve. Although RSCA and Pyrosequencing can achieve high-resolution results, their
applications in HLA typing will be gradually eliminated as the technology of gene chip and
sequencing continues to improve and the cost continues to decrease. HLA-chip genotyping is
still largely dependent on the known sequence. It cannot identify new alleles with unknown
sequence. At this moment, PCR-SBT technology has significant advantages over other HLA
typing methods in terms of accuracy, efficiency and automation. There are specialized software
and automatically loaded sequencing reagents for HLA typing by PCR-SBT. In addition, the
operation cost has been greatly reduced. In conclusion, PCR-SBT technology with HLA-chip
is the best method for HLA typing in research. With the reduction in the cost of automated
nucleic acid sequencing, this genotyping method will be widely used in the field of basic
research as well as in clinical transplantation.
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